Table 1. . Baseline characteristics of the included patients.

Descriptor	Number (%)
Total patient cohort	146 patients
Gender   – Male   – Female	88 (60.2) 58 (39.8)
Median age at diagnosis	62.9 years (range 22–95 years)
ECOG performance status   – 0   – 1   – 2   – ≥3   – Unknown	36 (24.7) 41 (28.1) 9 (6.2) 4 (2.7) 56 (38.4)
Stage   – II–III   – IV	15 (10.3) 131 (89.7)
Brain metastases	18 (12.3)
Raised LDH at immunotherapy commencement	74 (50.7)
Previous radiotherapy	65 (44.5)
Corticosteroids at time of treatment commencement†	12 (8.2)
Line of treatment   – 1   – 2   – 3   – 4 or more	64 (43.8) 51 (34.9) 17 (11.6) 11 (7.5)

Study patients numbered 146. The mean age was 63 years, 60% were male and most had an ECOG performance status of 0 to 1. The majority of the patients had stage IV disease, and most were receiving immunotherapy as first or second-line treatment.

^†(dose equivalent to 10 mg prednisolone per day).

ECOG: Eastern Cooperative Oncology Group.